Headlines about Accuray (NASDAQ:ARAY) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Accuray earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.619458115951 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Global Radiation Therapy Equipment Industry (prnewswire.com)
- Investors Love This Stock?: Accuray Incorporated (ARAY) (bitcoinpriceupdate.review)
- Global Cyber Knife Market 2018 – Accuray Incorporated, BrainLab, Elekta AB, Nucletron BV (roswellgazette.com)
- Global Healthcare Automation Market Competitive Analysis: Swisslog Holding AG, Intuitive Surgical, Accuray … (faircolumnist.com)
- Healthcare Stock to Track: Accuray Incorporated (ARAY) (stockdigest.info)
Accuray traded up $0.05, hitting $4.00, during trading hours on Wednesday, Marketbeat Ratings reports. 385,697 shares of the company traded hands, compared to its average volume of 727,145. The company has a current ratio of 1.62, a quick ratio of 0.97 and a debt-to-equity ratio of 3.00. Accuray has a one year low of $3.60 and a one year high of $6.15. The stock has a market cap of $340.41 million, a PE ratio of -11.11 and a beta of 1.71.
Several brokerages have weighed in on ARAY. BidaskClub cut Accuray from a “hold” rating to a “sell” rating in a research note on Saturday, June 23rd. Zacks Investment Research upgraded Accuray from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. ValuEngine upgraded Accuray from a “sell” rating to a “hold” rating in a research note on Friday, May 18th. Finally, Royal Bank of Canada set a $6.00 price objective on Accuray and gave the company a “hold” rating in a research note on Tuesday, April 10th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $7.21.
In other news, CFO Kevin Waters sold 14,265 shares of Accuray stock in a transaction on Tuesday, July 3rd. The stock was sold at an average price of $4.08, for a total transaction of $58,201.20. Following the sale, the chief financial officer now directly owns 313,995 shares in the company, valued at approximately $1,281,099.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Joshua Levine sold 34,235 shares of Accuray stock in a transaction on Tuesday, July 3rd. The stock was sold at an average price of $4.08, for a total value of $139,678.80. Following the sale, the chief executive officer now owns 1,392,518 shares in the company, valued at $5,681,473.44. The disclosure for this sale can be found here. Insiders have sold a total of 57,059 shares of company stock worth $232,801 over the last quarter. Company insiders own 3.90% of the company’s stock.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.